{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:01:35Z","timestamp":1790726495041,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":230,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IDCases"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.idcr.2026.e02736","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:25:51Z","timestamp":1787239551000},"page":"e02736","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Multiclass HIV drug resistance: Case series of treatment-experienced PLHIV with resistance to all antiretroviral classes in Northern Uganda"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0554-8024","authenticated-orcid":false,"given":"Francis","family":"Kayinda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian Betty","family":"Bakunzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Okello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charity","family":"Jurua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther M.","family":"Nasuuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idcr.2026.e02736_bib1","unstructured":"WHO. HIV drug resistance report 2021. HIV drug resistance report 2021 [Internet]. 2021, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-drug-resistance Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-drug-resistance."},{"issue":"s1","key":"10.1016\/j.idcr.2026.e02736_bib2","article-title":"HIV drug resistance: problems and perspectives","volume":"5","author":"Pennings","year":"2013","journal-title":"Infect Dis Rep"},{"issue":"9","key":"10.1016\/j.idcr.2026.e02736_bib3","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/infdis\/jix089","article-title":"Impact of HIV drug resistance on HIV\/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in Sub-Saharan Africa","volume":"215","author":"Phillips","year":"2017","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.idcr.2026.e02736_bib4","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/jac\/dkz561","article-title":"Prevalence of viral load suppression, predictors of virological failure and patterns of HIV drug resistance after 12 and 48 months on first-line antiretroviral therapy: a national cross-sectional survey in Uganda","volume":"75","author":"Ssemwanga","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idcr.2026.e02736_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13104-016-2309-7","article-title":"From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults","volume":"9","author":"Namakoola","year":"2016","journal-title":"BMC Res Notes"},{"issue":"5","key":"10.1016\/j.idcr.2026.e02736_bib6","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/QAI.0000000000001717","article-title":"HIV-1 drug resistance among Ugandan adults attending an urban out-patient clinic","volume":"78","author":"von Braun","year":"2018","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.idcr.2026.e02736_bib7","unstructured":"UPHIA. Uganda population-based HIV impact assessment report 20202021 [cited 2025 4th december 2025], https:\/\/phia.icap.columbia.edu\/wp-content\/uploads\/2022\/08\/UPHIA-Summary-Sheet-2020.pdf Available from: https:\/\/phia.icap.columbia.edu\/wp-content\/uploads\/2022\/08\/UPHIA-Summary-Sheet-2020.pdf."},{"key":"10.1016\/j.idcr.2026.e02736_bib8","unstructured":"Ministry of Health U. Consolidated guidelines for prevention and treatment of HIV in Uganda. 2016,"},{"key":"10.1016\/j.idcr.2026.e02736_bib9","unstructured":"WHO. Uganda launches HIV-AIDS test and treat guidelines2016 7th January 2024], https:\/\/www.afro.who.int\/news\/uganda-launches-hivaids-test-and-treat-guidelines-world-aids-day-commemoration Available from: https:\/\/www.afro.who.int\/news\/uganda-launches-hivaids-test-and-treat-guidelines-world-aids-day-commemoration."},{"key":"10.1016\/j.idcr.2026.e02736_bib10","unstructured":"Ministry of Health U. Consolidated guidelines for prevention and treatment of HIV in Uganda.2018."},{"key":"10.1016\/j.idcr.2026.e02736_bib11","unstructured":"Karunganwa N. VIRAL LOAD MONITORING; THE LAST MILE IN REALISING THE CONTINUUM OF RESPONSE FOR HIV CARE AND TREATMENT https:\/\/mets.or.ug\/2018 [cited 2025 23rd June 2025]. Available from: https:\/\/mets.or.ug\/viral-load-monitoring-the-last-mile-in-realising-the-continuum-of-response-for-hiv-care-and-treatment\/#:~:text=Up%20until%20August%202014%2C%20the,existing%20systems%20for%20EID%20testing."},{"key":"10.1016\/j.idcr.2026.e02736_bib12","unstructured":"Ministry of Health U. Consolidated guidelines for prevention and treatment of HIV in Uganda. Kampala, 2022. 380 p, https:\/\/dsduganda.com\/wp-content\/uploads\/2023\/05\/Consolidated-HIV-and-AIDS-Guidelines-20230516.pdf."},{"key":"10.1016\/j.idcr.2026.e02736_bib13","unstructured":"106a- HIV quarterly report [Internet]. 2023 [cited 5th January 2024]. Available from: https:\/\/hmis.health.go.ug\/dhis-web-commons\/security\/login.action#\/."},{"key":"10.1016\/j.idcr.2026.e02736_bib14","doi-asserted-by":"crossref","first-page":"901","DOI":"10.12688\/f1000research.121980.1","article-title":"Next-generation sequencing (NGS) reveals low-abundance HIV-1 drug resistance mutations among patients experiencing virological failure at the time of therapy switching in Uganda","volume":"11","author":"Namaganda","year":"2022","journal-title":"F1000Research"},{"key":"10.1016\/j.idcr.2026.e02736_bib15","unstructured":"HIV drug resistance database: Mutation analysis [Internet]. 2023 [cited 5\/01\/2024]. Available from: https:\/\/hivdb.stanford.edu\/hivdb\/by-patterns\/."},{"issue":"3","key":"10.1016\/j.idcr.2026.e02736_bib16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3390\/v16030399","article-title":"Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review","volume":"16","author":"Chu","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.idcr.2026.e02736_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-4690-9-63","article-title":"Human Immunodeficiency Virus Gag and protease: partners in resistance","volume":"9","author":"Fun","year":"2012","journal-title":"Retrovirology"},{"issue":"1","key":"10.1016\/j.idcr.2026.e02736_bib18","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1038\/s41598-018-23375-6","article-title":"Efficacy and safety of boosted darunavir-based antiretroviral therapy in HIV-1-positive patients: results from a meta-analysis of clinical trials","volume":"8","author":"Antinori","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.idcr.2026.e02736_bib19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bjid.2012.08.022","article-title":"High rate of virologic suppression with darunavir\/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in S\u00e3o Paulo, Brazil","volume":"17","author":"Vidal","year":"2013","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.idcr.2026.e02736_bib20","unstructured":"HIV drug resistance database: NRTI resistance notes [Internet]. Stanford University. 2022 [cited 05\/01\/2024]. Available from: https:\/\/hivdb.stanford.edu\/dr-summary\/resistance-notes\/NRTI\/."},{"issue":"8","key":"10.1016\/j.idcr.2026.e02736_bib21","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1517\/13543784.13.8.933","article-title":"Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy","volume":"13","author":"Buckheit Jr","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"10.1016\/j.idcr.2026.e02736_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/13596535221102690","article-title":"Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey","volume":"27","author":"Musengimana","year":"2022","journal-title":"Antivir Ther"},{"issue":"10","key":"10.1016\/j.idcr.2026.e02736_bib23","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/jac\/dkz261","article-title":"Rates of HIV-1 virological suppression and patterns of acquired drug resistance among fisherfolk on first-line antiretroviral therapy in Uganda","volume":"74","author":"Omooja","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idcr.2026.e02736_bib24","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12913-019-3963-y","article-title":"Challenges faced by caregivers of virally non-suppressed children on the intensive adherence counselling program in Uganda: a qualitative study","volume":"19","author":"Nasuuna","year":"2019","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.idcr.2026.e02736_bib25","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1186\/s12889-018-5964-x","article-title":"Low HIV viral suppression rates following the intensive adherence counseling (IAC) program for children and adolescents with viral failure in public health facilities in Uganda","volume":"18","author":"Nasuuna","year":"2018","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.idcr.2026.e02736_bib26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3851\/IMP2437","article-title":"Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review","volume":"18","author":"Stadeli","year":"2013","journal-title":"Antivir Ther"}],"container-title":["IDCases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250926002490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250926002490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:13:30Z","timestamp":1790723610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214250926002490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":26,"alternative-id":["S2214250926002490"],"URL":"https:\/\/doi.org\/10.1016\/j.idcr.2026.e02736","relation":{},"ISSN":["2214-2509"],"issn-type":[{"value":"2214-2509","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiclass HIV drug resistance: Case series of treatment-experienced PLHIV with resistance to all antiretroviral classes in Northern Uganda","name":"articletitle","label":"Article Title"},{"value":"IDCases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idcr.2026.e02736","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e02736"}}